Published 2022-04-08

Michael_Sundstrom_fotograf_Anne-Li_Engstrom.jpg

Michael Sundström. Photo: Anne-Li Engström

The Board of the Center for Molecular Medicine (CMM) has appointed Michael Sundström as the new Director of CMM. An experienced scientist, business leader and manager, Michael assumed his position on April 1, 2022.

Michael Sundström received his PhD from Uppsala University, followed by postdoctoral studies at Karolinska Institutet. He has more than 30 years of international experience in leading pharmaceutical and biotechnology organisations. He has held positions as Director for structure-based drug design and oncology Research & Development portfolio management at Pharmacia, as well as senior positions at Actar and Biovitrum. In 2003, he was one of the co-founders of the Structural Genomics Consortium (SGC) working at the University of Oxford as Chief Scientist. After moving to the positions of Managing Director for the Novo Nordisk Foundation Center for Protein Research in Copenhagen, and later Vice President of Discovery Research at Karolinska Development in Stockholm, he rejoined the SGC in mid-2014. As Scientific Director for the SGC Karolinska laboratory based at CMM, he mainly focuses on leading large European projects in partnership with the pharmaceutical industry. The projects aim to generate high-quality research tools, such as antibodies and chemical probes, for use in translational medicine research studies.

As CMM Director Michael Sundström will work in close cooperation with the Karolinska University Hospital, Karolinska Institutet and Region Stockholm in order to continue strengthening the connection between clinical and molecular research. In addition, together with the scientists, the CMM Board, CMM Steering Group and support personnel, he will further develop the Center as a leading and attractive cross-disciplinary research environment.

 

“I am very glad to have Michael Sundström on board as the new CMM Director. With his profile and experience, he is the right candidate to shoulder the responsibility of further developing our internationally recognised research center, with excellent foundations laid by previous Directors Professor Lars Terenius, Professor Lars Klareskog and Professor Helena Erlandsson Harris. With Michael Sundström leading the way, we are looking forward to continuing our close collaboration with the Karolinska University Hospital, Karolinska Institutet and Region Stockholm. I strongly believe Michael Sundström will lead CMM into the next phase. The future is bright.”, says Liselotte Jansson, Chair of the Board of the Center for Molecular Medicine.”

 

“It is truly exciting to take on this new role and set out to further develop CMM together with all the professionals who are the basis for its creative research environment. I believe that CMM has an excellent model for working at the lead of translational research, connecting the real health-related needs with intellectual capital, forefront scientific knowledge and technological possibilities. I am looking forward to further strengthening the organisation and our collective research outputs.”

About CMM

CMM is a foundation instituted by the Stockholm County Council (SLL), currently Region Stockholm and works in close collaboration between Karolinska University Hospital and Karolinska Institutet.